Therefore, a potential target of COVID‐19 treatment is increasing the plasma‐levels of ACE2 through exogenous ACE2‐therapy and thereby upregulating the ACE2/ANG‐(1‐7)/MAS‐axis and downregulating the opposing axis of RAAS. This evidence concerns the gene ACE2 and COVID-19.